VERTEX PHARMACEUTICALS INC / MA VRTX

Latest FY: 2025 Healthcare Biotechnology
Market Price $505.46
Market Cap $131.07B
P/E Ratio 32.99
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑8.9% YoY
$12.00B
3-Yr CAGR: 10.4%
Net Income ↑838.1% YoY
$3.95B
Net Margin: 32.9%
Free Cash Flow ↑504.1% YoY
$3.19B
FCF Yield: 2.44%
EPS (Diluted) ↑836.5% YoY
$15.32
Basic: $15.46
Return on Equity Efficiency
21.2%
ROA: 463.3%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (VRTX)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $1,702.2M $1,495.4M $-112.1M $-0.46 $236.1M $179.5M
FY 2017 $2,488.7M +46.2% $2,216.0M $263.5M +335.1% $1.04 +326.1% $844.9M $745.5M +315.2%
FY 2018 $3,047.6M +22.5% $2,638.1M $2,096.9M +695.8% $8.09 +677.9% $1,270.3M $1,174.8M +57.6%
FY 2019 $4,162.8M +36.6% $3,615.1M $1,176.8M -43.9% $4.51 -44.3% $1,569.3M $1,493.9M +27.2%
FY 2020 $6,205.7M +49.1% $5,469.4M $2,711.6M +130.4% $10.29 +128.2% $3,253.5M $2,993.7M +100.4%
FY 2021 $7,574.4M +22.1% $6,670.2M $2,342.1M -13.6% $9.01 -12.4% $2,643.5M $2,408.5M -19.5%
FY 2022 $8,930.7M +17.9% $7,850.4M $3,322.0M +41.8% $12.82 +42.3% $4,129.9M $3,925.2M +63.0%
FY 2023 $9,869.2M +10.5% $8,607.0M $3,619.6M +9.0% $13.89 +8.3% $3,537.3M $3,336.9M -15.0%
FY 2024 $11,020.1M +11.7% $9,489.6M $-535.6M -114.8% $-2.08 -115.0% $-492.6M $-790.3M -123.7%
FY 2025 $12,001.3M +8.9% $10,350.0M $3,953.2M +838.1% $15.32 +836.5% $3,631.4M $3,193.8M +504.1%
$

Valuation

Market Price $505.46
Market Cap $131.07B
Enterprise Value N/A
P/E Ratio 32.99
P/B Ratio 6.87
FCF Yield 2.44%
Dividend Yield N/A
Shares Outstanding 253,805,400
%

Profitability & Margins

Gross Margin 86.24%
Operating Margin 34.77%
Net Margin 32.94%
Return on Equity (ROE) 21.18%
Return on Assets (ROA) 463.28%
Asset Turnover 14.06x
Revenue 3-Yr CAGR 10.35%
🛡️

Financial Health & Liquidity

Current Ratio 0.29
Cash Ratio 1.71
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $5.08B
Total Debt N/A
Book Value / Share $73.54
💧

Cash Flow Efficiency

Operating Cash Flow $3.63B
Capital Expenditures (CapEx) $437.60M
Free Cash Flow $3.19B
OCF / Revenue 30.26%
FCF / Revenue 26.61%
FCF 3-Yr CAGR -6.64%
🏷️

Per Share Metrics

EPS (Diluted) $15.32
EPS (Basic) $15.46
Dividends / Share N/A
Book Value / Share $73.54
EPS YoY Growth 836.54%
🏛️

Balance Sheet (FY 2025)

Total Assets $853.30M
Total Liabilities $2.97B
Stockholders' Equity $18.67B
Current Assets $853.30M
Current Liabilities $2.97B